Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the current standard of care and new chemotherapy options for patients with advanced …

There are still remarkable disparities in the treatment of gastric cancer between the East and
West. Treatment outcomes for this disease have improved in Japan due to early detection …

Purpose In the randomized, multinational phase II/III trial (V325) of untreated advanced
gastric cancer patients, the phase II part selected docetaxel, cisplatin, and fluorouracil (DCF) …

Purpose Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for
the treatment for advanced gastric cancer. However, cisplatin has several disadvantages …

Purpose The purpose of this study was to define the contribution of docetaxel to combination
chemotherapy in the outcome of patients with advanced gastric or gastroesophageal …

Background PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan.
This randomized phase II study evaluated the efficacy and safety of single agent PEP02 …

Background: Docetaxel is widely used as a chemotherapeutic agent for gastric cancer
treatment. A combined regimen with sunitinib demonstrated a synergistic antitumour effect in …

Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the role and evolution of chemotherapy for advanced gastric cancer. Discuss results of …

Docetaxel-based chemotherapy appears to have considerable promise in advanced gastric
cancer. In phase II studies of single agent docetaxel, response rates (RRs) of 17% to 24 …

Purpose We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine
the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its …